Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

British Journal of Haematology

Volumn 164, Issue 6, 2014, Pages 858-866

  Westwood, John Paul ^a   Langley, Kathryn ^a   Heelas, Edward ^a   Machin, Samuel J ^a   Scully, Marie ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

ADAMTS13; Complement; Cytokines; T cells; Thrombotic Thrombocytopenic Purpura

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; TH1 CELL; TH17 CELL; TH2 CELL; THROMBOTIC THROMBOCYTOPENIC PURPURA; YOUNG ADULT;

ADAMTS13; COMPLEMENT; CYTOKINES; T CELLS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; COHORT STUDIES; COMPLEMENT ACTIVATION; CYTOKINES; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; YOUNG ADULT;

EID: 84894705729     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12707     Document Type: Article

References (25)

1. Alegretti, A.P., Schneider, L., Piccoli, A.K. & Xavier, R.M. (2012) The role of complement regulatory proteins in peripheral blood cells of patients with systemic lupus erythematosus: review. Cellular Immunology, 277, 1-7.
2. Chow, K.V., Carroll, R., Branley, P., Nicholls, K., Becker, G. & Hogan, C. (2007) Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Intern Med J, 37, 329-332.
3. Elkon, K.B. & Santer, D.M. (2012) Complement, interferon and lupus. Current Opinion in Immunology, 24, 665-670.
4. Furlan, M., Robles, R., Solenthaler, M. & Lammle, B. (1998) Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood, 91, 2839-2846.
5. Gabay, C. (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther, 8 (Suppl 2), S3.
6. Hillmen, P., Muus, P., Roth, A., Elebute, M.O., Risitano, A.M., Schrezenmeier, H., Szer, J., Browne, P., Maciejewski, J.P., Schubert, J., Urbano-Ispizua, A., de Castro, C., Socie, G. & Brodsky, R.A. (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 162, 62-73.
7. Iyer, S.S. & Cheng, G. (2012) Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Critical Reviews in Immunology, 32, 23-63.
8. Kavanagh, D. & Goodship, T. (2010a) Genetics and complement in atypical HUS. Pediatric Nephrology(Berlin, Germany), 25, 2431-2442.
9. Kavanagh, D. & Goodship, T.H. (2010b) Atypical hemolytic uremic syndrome. Current Opinion in Hematology, 17, 432-438.
10. Kavanagh, D. & Goodship, T.H. (2011) Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program, 2011, 15-20.
11. Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Cohen, D.R., Gregory, W.M. & Hillmen, P. (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood, 117, 6786-6792.
12. Klos, A., Tenner, A.J., Johswich, K.O., Ager, R.R., Reis, E.S. & Kohl, J. (2009) The role of the anaphylatoxins in health and disease. Molecular Immunology, 46, 2753-2766.
13. Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A. & Miyata, T. (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. British Journal of Haematology, 129, 93-100.
14. Lucisano Valim, Y.M. & Lachmann, P.J. (1991) The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clinical and Experimental Immunology, 84, 1-8.
15. Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M. & Shiina, M. (2012) IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond), 122, 143-159.
16. Mollnes, T.E., Garred, P. & Bergseth, G. (1988) Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clinical and Experimental Immunology, 73, 484-488.
17. Reti, M., Farkas, P., Csuka, D., Razso, K., Schlammadinger, A., Udvardy, M.L., Madach, K., Domjan, G., Bereczki, C., Reusz, G.S., Szabo, A.J. & Prohaszka, Z. (2012) Complement activation in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 10, 791-798.
18. Ricklin, D. & Lambris, J.D. (2013) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol, 190, 3831-3838.
19. Ruiz-Torres, M.P., Casiraghi, F., Galbusera, M., Macconi, D., Gastoldi, S., Todeschini, M., Porrati, F., Belotti, D., Pogliani, E.M., Noris, M. & Remuzzi, G. (2005) Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis, 93, 443-452.
20. Scully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I. & Machin, S.J. (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 136, 451-461.
21. Scully, M., Hunt, B.J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B., Machin, S.J. & for the British Committee for Standards in Haematology (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 158, 323-335.
22. Taylor, C.M., Machin, S., Wigmore, S.J., Goodship, T.H. & the working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society (2010) Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. British Journal of Haematology, 148, 37-47.
23. Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 1585-1594.
24. Wong, E.K., Goodship, T.H. & Kavanagh, D. (2013) Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology, 56, 199-212.
25. Wu, T.C., Yang, S., Haven, S., Holers, V.M., Lundberg, A.S., Wu, H. & Cataland, S.R. (2013) Complement Activation and Mortality During an Acute Episode of Thrombotic Thrombocytopenic Purpura. Journal of Thrombosis and Haemostasis, 11, 1925-1927.